Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Pollina

Interventional Pain Medicine Saint Clair Shores, MI Medical Doctor

NPI 1255635405 CMS profile 329064

25311 Little Mack Ave Ste B, Saint Clair Shores, MI 48081

Open in the dashboard

General payments

$144,493

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,200 paid to institutions, not to them · program year 2022

Through program year 2025, Ryan Pollina of Saint Clair Shores, MI is reported in the CMS Open Payments database as having received $144,493 across 217 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,200 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,608 27
2024 General $18,785 44
2023 General $35,456 32
2022 General $34,491 28
2021 General $10,253 21
2019 General $32,900 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Pollina
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ryan Pollina were reported at $12,608. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ryan Pollina Interventional Pain Medicine median Middle half National median
2019 $32,900 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $10,253 $552 $167–$1,554 $132
2022 $34,491 $605 $187–$1,924 $149
2023 $35,456 $671 $195–$1,915 $160
2024 $18,785 $684 $206–$1,837 $164
2025 $12,608 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stimwave Technologies Incorporated $73,864 86 payments
  2. Curonix LLC $65,550 71 payments
  3. Vertiflex, Inc. $1,825 12 payments
  4. Nevro Corp. $1,751 13 payments
  5. Boston Scientific Corporation $792 19 payments
  6. Vertos Medical, Inc. $189 4 payments
  7. Nalu Medical, Inc. $159 2 payments
  8. Checkpoint Surgical, Inc $117 1 payment
  9. Averitas Pharma Inc. $59 2 payments
  10. Relievant Medsystems, Inc. $53 1 payment
  11. Other $134 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $113,356 42 payments
  2. Travel and Lodging $20,617 54 payments
  3. Food and Beverage $6,373 111 payments
  4. Entertainment $2,907 5 payments
  5. Honoraria $1,000 1 payment
  6. Gift $239 4 payments
Products named General payments · program years 2019–2025
  1. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $65,175 70 payments
  2. StimQ Freedom-8A Receiver Kit Channel A US w/ Receiver $42,645 29 payments
  3. StimQ Receiver Stimulator Kit Channel A US w/Receiver $42,645 29 payments
  4. Freedom-8A Receiver Kit Channel A US w/ Receiver $42,645 29 payments
  5. StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver $42,645 29 payments
  6. Freedom-4A Receiver Kit Channel A US w/ Receiver $34,395 25 payments
  7. Freedom 4A Receiver Kit Channel A US w Receiver $10,150 10 payments
  8. Freedom 8A Receiver Kit Channel A US w Receiver $1,900 6 payments
  9. StimQ Freedom 4A Receiver Kit Channel A US Receiver $1,900 6 payments
  10. StimQ Freedom 8A Receiver Kit Channel A US w Receiver $1,900 6 payments
  11. Other $7,121 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,543

Median for Pain Management: 951

Drug cost

$72,609

Median for Pain Management: $26,034

Branded share of claims

41.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 684 $13,023
Oxycontin Oxycodone Hcl Brand 24 $9,639
Buprenorphine Generic 31 $8,541
Xtampza Er Oxycodone Myristate Brand 16 $8,168
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 39 $6,971
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 214 $3,293
Gabapentin Generic 296 $3,250
Pregabalin Generic 169 $2,719
Lidocaine Generic 41 $2,642
Oxycodone Hcl Generic 89 $2,574

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$179,696

Of which drugs: $802

Medicare patients

396

Average age 75

Services billed

3,872

249 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Diabetes 32%
Chronic kidney disease 28%
Depression 27%
COPD 24%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 163 1,002 $703
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 80 1,242 $99

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $28
$28 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record